Clinical Trial Matching

Clinical Trial Matching is the NLP task of automatically determining whether a specific patient is eligible for a given clinical trial — parsing the complex eligibility criteria of trial protocols and matching them against structured and unstructured patient data from electronic health records, directly addressing the critical bottleneck that 85% of clinical trials fail to meet enrollment targets on time.

What Is Clinical Trial Matching?

• Problem: Every clinical trial defines inclusion criteria (conditions that qualify a patient) and exclusion criteria (conditions that disqualify a patient) — together averaging 30-50 criteria per trial.
• Scale: ClinicalTrials.gov lists 450,000+ registered trials, each with complex eligibility criteria written in medical language.
• Patient Data: EHR data includes ICD diagnosis codes, lab values, medications, procedure history, pathology reports, and clinician notes — structured and unstructured.
• Task: For a given (patient, trial) pair, classify as Eligible / Ineligible / Insufficient Information.
• Benchmark: n2c2 2018 Track 1 — 288 patients, 13 chronic disease criteria; TREC Clinical Trials 2021/2022 — information retrieval + eligibility classification.

The Eligibility Criteria Parsing Problem

A real trial exclusion criterion:

"Patients with prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways."

Parsing this requires:
- Entity Recognition: Anti-PD-1, anti-PD-L1, anti-CTLA-4 are drug class designations, not trade names.
- Semantic Scope: "Any other antibody specifically targeting T-cell co-stimulation" requires knowledge of immunology to operationalize — is nivolumab excluded? (Yes — anti-PD-1.) Is bevacizumab excluded? (No — anti-VEGF.)
- Temporal Logic: "Prior treatment" vs. "current treatment" vs. "within 28 days" — temporal scoping is critical.
- Negation and Exception Handling: "Unless washout period of ≥6 weeks has elapsed" — a disqualifying criterion transforms into a qualifying condition post-washout.

Technical Approaches

Rule-Based Systems: Manually author extraction rules for each criterion type. High precision, brittle, requires clinical informatics expertise.

Criteria2Query: Generate SQL or FHIR queries from natural language criteria — automates EHR lookup but requires robust NL-to-query translation.

BERT-based Classifiers:
- Fine-tune ClinicalBERT/BioBERT on (criteria text, patient fact) → eligible/ineligible pairs.
- n2c2 2018 best system: ~91% micro-F1 across 13 criteria types.

LLM-based Reasoning (GPT-4):
- Chain-of-thought over structured patient data and parsed criteria.
- Achieves ~85%+ on n2c2 but requires careful prompt engineering for logical connectives.

Performance (n2c2 2018 Track 1)

Why Clinical Trial Matching Matters

• Trial Enrollment Crisis: 85% of clinical trials fail to meet enrollment targets. Under-enrollment leads to underpowered trials, delayed approvals, and billions in wasted investment.
• Patient Access to Innovation: Many eligible patients who would benefit from experimental treatments are never identified — automated matching extends clinical trial access to patients whose physicians are not trial investigators.
• Site Selection: Sponsors can use automated patient screening to identify which clinical sites have sufficient eligible patient populations for efficient enrollment.
• Precision Enrollment: AI matching improves trial population homogeneity — enrolling patients who precisely meet criteria, not approximations, improves trial validity and reduces confounding.
• Rare Disease Trials: For rare diseases (prevalence <200,000), AI matching is essential — manual review of 10 million EHR records to find 50 eligible patients is infeasible without automation.

Clinical Trial Matching is the AI enrollment engine for clinical research — automating the analysis of complex eligibility criteria against patient health records at scale, directly addressing the enrollment crisis that delays development of new treatments for patients who need them.